Eliz­a­beth War­ren pro­pos­es us­ing com­pul­so­ry li­cens­ing, an­titrust ac­tions to break bio­phar­ma’s con­trol of drug pric­ing — and here are the block­busters she’s tar­get­ing first

11 hours ago
Bioregnum
Pharma

Alzheimer's break­through? Not so fast — ex­perts poke holes in da­ta un­der­ly­ing Chi­na's sur­prise ap­proval

Last week
China

As CRISPR hori­zons cloud, a start­up fo­cus­es on the next big thing with pow­er­house po­ten­tial — the RNA edit­ing plat­form

Last week
Startups

Worth­less? Short at­tack on Fi­bro­Gen claims their ane­mia drug roxa has a lethal Achilles’ heel — and it’s go­ing down

2 weeks ago
Pharma
R&D

Vivek Ra­maswamy trades top ex­ecs and adds stealthy vant to $3B sale, while his new part­ner toss­es My­ovant $350M

3 weeks ago
Deals

Google’s ven­ture arm re­cruits a Har­vard/Tesaro vet to help plant the seeds for a sec­ond on­col­o­gy R&D rev­o­lu­tion

3 weeks ago
People
Venture

From $0 to $12B in an in­stant. Here's why bio­phar­ma loves risky Alzheimer's stud­ies

4 weeks ago
Bioregnum
Pharma

The $102B club: The top 15 R&D spenders in the glob­al bio­phar­ma busi­ness — 2019 edi­tion

Last month
R&D

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron talks about a new era at GSK

Last month

Court green-lights Clo­vis case af­ter de­tail­ing ev­i­dence the board ‘ig­nored red flags’ on false safe­ty and ef­fi­ca­cy da­ta

Last month
R&D

‘There are mo­ments’: Sanofi’s new CEO is think­ing through the R&D strat­e­gy — and on­col­o­gy will be key

Last month
Bioregnum

Biotechs are spend­ing record sums on R&D — should that wor­ry you at least a lit­tle?

Last month
R&D

A mi­cro­cap biotech salves old wounds with pos­i­tive PhII re­port on sta­tus epilep­ti­cus, but plen­ty of ques­tions re­main

Last month
R&D

Ver­tex buys the top spot on the list of the biggest pre­clin­i­cal M&A deals. Were they robbed or was it a steal?

2 months ago
Deals

Worst. biotech. deal. ever? Turns out Ab­b­Vie has plen­ty of com­pe­ti­tion for that ti­tle

2 months ago
Deals
Pharma

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

3 months ago
Regulatory

Bay­er’s $240M up­front for Blue­Rock ac­qui­si­tion puts them in the high rollers club for pre­clin­i­cal biotech buy­outs

3 months ago
Deals
Discovery

No­var­tis' $18.5B in M&A un­der Vas Narasimhan says a lot about their care­ful — but op­por­tunis­tic — deal strat­e­gy

3 months ago
Deals

What makes Hal Bar­ron tick? Look at the peo­ple he’s team­ing up with at GSK

3 months ago
Bioregnum
People

As Take­da ab­sorbs Shire’s R&D ops, the fo­cus is on re­plac­ing a cen­tral­ized com­mand mod­el with a ‘light touch’ in a re­struc­tured glob­al or­ga­ni­za­tion

3 months ago
Deals
R&D

H1 analy­sis: The high-stakes ta­ble in the biotech deals casi­no is pay­ing out some record-set­ting win­nings

4 months ago
Deals

The top 15 mega-deals in bio­phar­ma: Ab­b­Vie and Bris­tol-My­ers ac­qui­si­tions stir fresh de­bate over what's too big to buy

4 months ago
Deals

Gene ther­a­py R&D deals turn red hot as Big Phar­ma steps up to play

5 months ago
Cell/Gene Tx
Deals

Bio­phar­ma BD teams are speed­ing in­to the fast lane — cash in hand — as deal­mak­ing con­tin­ues to heat up in Q1 of­fen­sive

6 months ago
Pharma
1234 Next page Last page